BELLUS Closes Buy of VC-Backed Thallion Pharmaceuticals
The acquisition of Montréal-based Thallion Pharmaceuticals Inc. by drug discovery company BELLUS Health Inc. for $6.3 million has been completed. Thallion, which develops pharmaceutical products in the areas of infectious disease and oncology, was formed in 2007 through the merger of Ecopia Biosciences Inc. and Caprion Pharmaceutical Inc. It was backed by the Fonds de solidarité des travailleurs du Québec FTQ and other investors.
16 August 2013•4 mins read
